News
Moderna shares surged 9.5% amid legal backlash against vaccine policy changes. Will it be a turning point for MRNA which is ...
Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...
Moderna shares surged 9.5% amid legal backlash against vaccine policy changes. Will it be a turning point for MRNA which is struggling with weaker sales?
Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial. In a Phase 3 study, the ...
The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.
The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.
Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...
Moderna's flu vaccine shows positive late-stage trial results, paving way for combination Covid shot
The phase three study data clears the path forward for Moderna’s combination jab targeting Covid-19 and influenza.
Key Takeaways The S&P 500 fell 0.1% on Tuesday, July 8, 2025, after President Trump extended the deadline for "reciprocal" tariffs and discussed a 50% levy on imported copper.Shares of Fair Isaac, ...
The mRNA drug developer said it will begin discussing approval with the FDA, which has adopted stricter vaccine review ...
RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...
In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results